Evidence map›Paper›PMID 37653524›Full record

Observational studyItalian journal of pediatrics2023

Serum endocan as a predictive biomarker of cardiovascular risk in obese pediatric patients.

Carmela Morace, Selenia Lorenza Curatola, Giuseppe Mandraffino, Michele Scuruchi, Angela Elvira Serrano', Angelo Tropeano, Fortunato Lombardo, Giuseppina Salzano, Giovanni Squadrito, Antonio Giovanni Versace and 1 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Italian journal of pediatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Carmela Morace *Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Selenia Lorenza Curatola *Department of Human Pathology of Adulthood and Childhood, Unit of Pediatrics, University of Messina, Via Consolare Valeria 98126, Messina, Italy.
Giuseppe MandraffinoDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Michele ScuruchiDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Angela Elvira Serrano'Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Angelo TropeanoDepartment of Human Pathology of Adulthood and Childhood, Unit of Pediatrics, University of Messina, Via Consolare Valeria 98126, Messina, Italy.
Fortunato LombardoDepartment of Human Pathology of Adulthood and Childhood, Unit of Pediatrics, University of Messina, Via Consolare Valeria 98126, Messina, Italy.
Giuseppina SalzanoDepartment of Human Pathology of Adulthood and Childhood, Unit of Pediatrics, University of Messina, Via Consolare Valeria 98126, Messina, Italy.
Giovanni SquadritoDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Antonio Giovanni VersaceDepartment of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
Mariella ValenziseDepartment of Human Pathology of Adulthood and Childhood, Unit of Pediatrics, University of Messina, Via Consolare Valeria 98126, Messina, Italy. mvalenzise@unime.it.ORCID http://orcid.org/0000-0003-4410-9684
University of Messina · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEndocan is a soluble dermatan sulfate proteoglycan (50 kDa) secreted by endothelial cells and expressed by dermal, coronary, pulmonary and adipose tissue microvasculature. It plays an important role in the pathogenesis of vascular disorders, inflammatory state, endothelium dysfunction and neoangiogenesis. Aims of the study were to compare fasting serum endocan levels between children with obesity and healthy controls and to investigate the relationships between endocan, body mass index (BMI) and other indices of cardiometabolic risk.

methodsThis single-center, observational, retrospective study included 19 pediatric patients with obesity aged 11.94 ± 0.52 years and 19 lean matched controls. Each patient underwent clinical and auxological examination and laboratory investigations including routine organs function tests and lipid profile. Homeostasis model assessment of insulin resistance (HOMA-IR) was calculated. Fasting endocan serum levels were measured using an enzyme-linked immunosorbent assay (ELISA).

resultsCompared to healthy subjects, serum endocan levels were found to be significantly upraised in children with obesity. Endocan resulted significantly correlated with insulin levels (rho 0.47; p = 0.04); in addition, an association with HOMA-IR values with a trend toward the statistical significance (rho 0.43; p = 0.07) was found. No significant correlation with fasting blood glucose values and lipid serum levels was demonstrated. Although not statistically significant, a correlation between endocan and the presence and grading of liver steatosis on ultrasound (rho 0.51; p = 0.08 and rho 0.51; p = 0.08, respectively) was found.

conclusionsThese findings confirm the association between endothelial damage and insulin resistance in children with obesity. Endocan could be used as a biomarker of early endothelial dysfunction in children with obesity and could be a valid predictor of future cardiovascular risk in adulthood.

Indexed as

Cardiovascular DiseasesInsulin ResistanceBiomarkersChildEndothelial CellsHeart Disease Risk FactorsHumansLipidsRetrospective StudiesRisk FactorsBiomarkersLipidsCardiovascular riskChildrenEndocanObesity

Identifiers

PMID37653524
PMCPMC10468868
OpenAlexW4386330270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.